|1.||Warkentin, Theodore E: 10 articles (09/2011 - 06/2002)|
|2.||Jern, Christina: 8 articles (10/2014 - 07/2005)|
|3.||Rothwell, Peter M: 7 articles (10/2015 - 03/2011)|
|4.||Adams, Harold P: 7 articles (05/2015 - 10/2003)|
|5.||Jood, Katarina: 7 articles (10/2014 - 07/2005)|
|6.||Heo, Ji Hoe: 7 articles (08/2014 - 01/2007)|
|7.||Munshi, Anjana: 7 articles (04/2014 - 09/2010)|
|8.||Kaul, Subhash: 7 articles (04/2014 - 09/2010)|
|9.||Jyothy, A: 6 articles (04/2014 - 09/2010)|
|10.||Sharma, Vandana: 6 articles (04/2014 - 09/2010)|
|1.||Venous Thrombosis (Deep-Vein Thrombosis)
10/01/1998 - "The absolute difference in the incidence of deep vein thrombosis was 12.3% in favor of danaparoid. "
01/01/1992 - "Deep vein thrombosis occurred in 2 of 50 (4%) in the Orgaran group and 7 of 25 (28%) in the placebo group (p = 0.005). "
01/01/1992 - "Prevention of deep vein thrombosis following total hip replacement surgery by Orgaran. "
01/01/1992 - "In both, Orgaran was significantly more effective in reducing the frequency of deep vein thrombosis without producing an increase in bleeding complications or other side effects."
01/01/1992 - "Orgaran in the prevention of deep vein thrombosis in stroke patients."
12/01/1990 - "A prospective, randomized, double-blind, controlled trial is needed to establish the potential efficacy of Org 10172 in patients who suffer acute or progressing ischemic stroke."
09/01/2015 - "Stroke etiology was determined by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria, and the severity of stroke was defined according to the National Institute of Health Stroke Scale score. "
07/01/2015 - "Ischemic stroke subtypes were classified according to the Trial of Org 10172 in Acute Stroke Treatment criteria. "
07/01/2015 - "The type of acute ischemic stroke was classified according to the Trial of Org 10172 in Acute Stroke Treatment classification. "
07/01/2015 - "Stroke etiology in each patient was classified according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. "
04/01/2015 - "One death occurred in danaparoid-treated group due to persistent thrombocytopenia. "
02/01/2003 - "Danaparoid 2.0-2.4 units/kg/h achieved anti-Xa levels of 0.2-0.4 U/mL, but thrombocytopenia failed to resolve. "
02/01/1994 - "One patient was treated with ORG 10172 and thrombocytopenia resolved."
01/01/1992 - "Upon treatment with Org 10172 platelet counts normalized in 9 patients, in 1 patient thrombocytopenia was unrelated to parenteral anticoagulation, in 1 patient platelet count normalized after discontinuation of Org 10172. "
01/01/1992 - "This paper summarises the results of intravenous or subcutaneous Orgaran treatment in 57 of 67 Australian patients, in whom the diagnosis of HIT was reasonably confirmed by exclusion of other causes of thrombocytopenia and by objective tests. "
05/01/2010 - "Furthermore, our data suggest that the haemostatic agent, rFVIII, might be effective in treatment of bleeding complications induced by danaparoid."
05/01/2007 - "Five patients showed bleeding complications, seven fetal losses were documented, but there was no association with the use of danaparoid. "
01/01/2007 - "Danaparoid administered by a continuous infusion of 100 anti-Xa-U/hour after a loading dose of 3,500 anti-Xa-U elicited target anti-Xa levels from 2 to 12 hours after the loading dose, without bleeding or thromboembolic events during the described CVVH treatment in patients with suspected HIT."
06/01/2006 - "Post-operative bleeding limits danaparoid use for cardiopulmonary by-pass surgery. "
01/01/2006 - "Major bleeding (by day 7) occurred in 7/62 (11.3%) and 16/56 (28.6%) of danaparoid-treated and control patients, respectively (p=0.0211). "
01/01/1992 - "Two studies evaluating the effect of Orgaran prophylaxis on the incidence of postoperative thrombosis in hip fracture surgery are reported. "
02/01/2011 - "Anticoagulation with 2500 units danaparoid per day was sufficient for therapy of thrombosis and no rebleeding occurred."
04/01/2010 - "In these patients danaparoid use was relatively safe (4 unprovoked non-fatal major bleeds) and efficacious in protecting the circuit (95% no clotting problem) or patient (6 thromboses: 4 fatal or leading to danaparoid discontinuation). "
06/01/2006 - "Clinical cross-reactivity of danaparoid (new/persistent platelet count reduction and/or new/extended thrombosis) was confirmed serologically in 23 of 36 patients with positive pretreatment serological danaparoid cross-reactivity and in 22 of 32 additional patients tested at the time of the new event, i.e. "
12/01/1997 - "From the 4th postoperative day 750 IU of danaparoid were administered twice daily subcutaneously for thrombosis prevention. "
|5.||Dalteparin (Dalteparin Sodium)
|8.||Tissue Kallikreins (Tissue Kallikrein)
|9.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|1.||Hip Replacement Arthroplasty (Total Hip Replacement)
|4.||Renal Replacement Therapy (Therapies, Renal Replacement)
|5.||Transurethral Resection of Prostate (TURP)